1. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial 
Åsa Lindholm, M.D., Marie Bixo, M.D., Ph.D., Inger Björn, M.D., Ph.D., Pål Wölner-Hanssen, M.D., Ph.D., Mats Eliasson, M.D., Ph.D., Anders Larsson, M.D., Ph.D., Owe Johnson, M.D., Ph.D., Inger Sundström Poromaa, M.D., Ph.D. 
Fertility and Sterility 
Volume 89, Issue 5, Pages (May 2008)
DOI: /j.fertnstert
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Mean ± SEM weight reduction (top) and mean ± SEM BMI reduction (bottom) after 24 weeks of treatment with sibutramine 15 mg once daily (n = 21) and placebo (n = 20), both together with brief lifestyle intervention. Patients dropping out of the study are kept in the analysis as far as possible. After 6 months the sibutramine group had lost 7.8 ± 5.1 kg and the placebo group 2.8 ± 6.2 kg; main effect of treatment: F(1, 30) = 10.12; P<.01, treatment by time interaction: F(1, 30) = 5.01; P<.05. Compared with placebo, sibutramine treatment resulted in reduced BMI; main effect of treatment: F(1, 30) = 11.18; P<.01, treatment by time interaction F(1, 30) = 6.00; P<.05.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions